Aptevo Advances APVO451 toward IND-enabling Studies, Optimizes Scalable Manufacturing

Aptevo is optimizing trispecific candidates for scalable manufacturing and expects IND-enabling studies for lead candidate APVO451 in 1H2027.Key Highlights:Original SEC Filing: Aptevo Therapeutics Inc. [ APVO ] - 8-K - Sep. 24, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…